Processa Pharmaceuticals, Inc.

Processa Pharmaceuticals is a clinical-stage biopharmaceutical company focused on developing modified chemotherapy drugs designed to improve the safety and efficacy profiles of existing FDA-approved oncology treatments. The company's approach involves altering the metabolism and distribution of established cancer drugs while preserving their anti-tumor mechanisms. This strategy aims to reduce side effects and enhance therapeutic outcomes across multiple cancer types.

The company's pipeline comprises three oncology programs at various development stages. PCS3117, a gemcitabine modification, has completed Phase 2a trials for pancreatic, biliary tract, lung, ovarian, and breast cancers. PCS6422, a capecitabine combination, is in Phase 2 clinical trials targeting metastatic colorectal, gastrointestinal, breast, and pancreatic cancers. PCS11T, an irinotecan derivative, remains in pre-clinical development. Beyond oncology, Processa is developing PCS12852 in Phase 2B trials for gastroparesis treatment and PCS499 for glomerular disease.

Based in Hanover, Maryland, Processa operates as a lean organization with approximately 10 full-time employees. The company has established license agreements with multiple partners including Elion Oncology, Ocuphire Pharma, Aposense, Yuhan Corporation, and CoNCERT Pharmaceuticals to support its drug development efforts. Processa was incorporated in Delaware and incorporated as a company in 2017.